Search by Drug Name or NDC
NDC 59212-0681-10 Zonegran 25 mg/1 Details
Zonegran 25 mg/1
Zonegran is a ORAL CAPSULE in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Concordia Pharmaceuticals Inc.. The primary component is ZONISAMIDE.
MedlinePlus Drug Summary
Zonisamide is used in combination with other medications to treat certain types of seizures. Zonisamide is in a class of medications called anticonvulsants. It works by decreasing abnormal electrical activity in the brain.
Related Packages: 59212-0681-10Last Updated: 12/01/2022
MedLinePlus Full Drug Details: Zonisamide
Product Information
| NDC | 59212-0681 |
|---|---|
| Product ID | 59212-681_93089228-c3a5-4e71-baac-58a930480f2b |
| Associated GPIs | 72600090000105 |
| GCN Sequence Number | 053367 |
| GCN Sequence Number Description | zonisamide CAPSULE 25 MG ORAL |
| HIC3 | H4B |
| HIC3 Description | ANTICONVULSANTS |
| GCN | 20831 |
| HICL Sequence Number | 021140 |
| HICL Sequence Number Description | ZONISAMIDE |
| Brand/Generic | Brand |
| Proprietary Name | Zonegran |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | Zonisamide |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | CAPSULE |
| Route | ORAL |
| Active Ingredient Strength | 25 |
| Active Ingredient Units | mg/1 |
| Substance Name | ZONISAMIDE |
| Labeler Name | Concordia Pharmaceuticals Inc. |
| Pharmaceutical Class | Anti-epileptic Agent [EPC], Carbonic Anhydrase Inhibitors [MoA], Decreased Central Nervous System Disorganized Electrical Activity [PE], P-Glycoprotein Inhibitors [MoA], Sulfonamides [CS] |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA020789 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 59212-0681-10 (59212068110)
| NDC Package Code | 59212-681-10 |
|---|---|
| Billing NDC | 59212068110 |
| Package | 100 CAPSULE in 1 BOTTLE (59212-681-10) |
| Marketing Start Date | 2000-03-27 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |